Concerns Rise Over Safety and Misuse of Popular Weight Loss Injections

The Medicines and Healthcare products Regulatory Agency (MHRA) has recently reported ten deaths allegedly associated with weight loss injections, including Wegovy and Ozempic. Additionally, 7,228 instances of adverse reactions such as nausea, vomiting, and diarrhea have been recorded. These reactions resulted in 68 hospitalizations, suggesting an increase in reported cases.

It is important to note that the reported deaths and adverse reactions do not establish a direct causation, as underlying health issues or other medications may have contributed. The MHRA urges healthcare professionals to remain vigilant for unauthorized uses of these drugs, typically glucagon-like peptide-1 receptor agonists (GLP-1RAs), often misused for aesthetic weight loss rather than their intended therapeutic purposes.

UK Health Secretary Wes Streeting emphasized that such injections are intended for individuals struggling with obesity, not for cosmetic purposes. They should be administered responsibly under medical supervision. Despite their potential to aid weight loss when combined with proper diet and exercise, using these drugs improperly or purchasing them online without prescription can pose serious health risks.

To address these concerns, the General Pharmaceutical Council is considering new safeguards for online pharmacies, ensuring proper verification of patient information, including weight and BMI, before prescribing or dispensing these medications. The focus remains on ensuring such drugs are used safely and appropriately to assist those genuinely in need.